

89-282538/39	B03	SAWA 15.02.88 *JO 1207-237-A	B(4-C2, 7-A2, 12-C9, 12-G7)
SAWAI SEIYAKU KK		15.02.88-JP-032150 (21.08.89) A61k-31/70 C07h-13/06	
Tumour necrosis factor inducer with low toxicity - contains trehalose dimycolate C89-125215			
<p>TNF inducer contains trehalose dimycolate as active component.</p> <p>USE/ADVANTAGE - Trehalose dimycolate is combined with second inducer e.g. LPS, and TNF can be induced significantly. The toxicity of trehalose dimycolate is very low, and it can be prep'd. to common dosage forms. Any pharmaceutically permitted additives can be added by common method, e.g. tablets, capsules, powders, liposome, emulsions for injections, suspensions for injections etc. Common doses for an adult are 10-2000 mg pref. 500-1000 mg per day. After 1-3 days of admin., almost the same amt. of the second inducer is administered to induce TNF. IN an example egg yolk phosphatidyl choline (5 micro mole) and trehalose dimycolate (1 mg) were dissolved in CHCl₃, charged into eggplant flask, and CHCl₃ was distilled away in vacuo on 25-30 deg.C water bath to form thin membrane at inner wall of the flask. Phosphate buffer saline (pH 7.0, 1ml) was charged and shaken until the thin membrane was exfoliated. The prep'd. liposome was frozen by dry ice.meOH, and lyophilised by freezing drying machine. Lyophilised dry powder of trehalose dimycolate contg. liposome was obt'd. (4pp Dwg.No.0/0)</p>			

Best Available Copy